Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements Guidance for Industry

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <u>https://www.regulations.gov</u>. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document, contact (CDER) Elizabeth Pepinsky, 301-796-1200; (CBER) Office of Communication, Outreach and Development, 800-835-4709 or 240-402-8010; or (CVM) Thomas Moskal, 240-402-6251.

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Veterinary Medicine (CVM)

> October 2018 Advertising

Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements Guidance for Industry

Additional copies are available from:

Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353 *Email: druginfo@fda.hhs.gov* http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or Office of Communication, Outreach and Development Center for Biologics Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 71, Room 3128 Silver Spring, MD 20993-0002 Phone: 800-835-4709 or 240-402-8010 *Email: ocod@fda.hhs.gov* http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or Policy and Regulations Staff, HFV-6 Center for Veterinary Medicine Food and Drug Administration 7519 Standish Place. Rockville. MD 20855 http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm

> U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Veterinary Medicine (CVM)

> > October 2018 Advertising

Draft — Not for Implementation

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	BACKGROUND	2
III.	RECOMMENDATIONS FOR PRESENTING QUANTITATIVE EFFICACY ANI RISK INFORMATION IN DIRECT-TO-CONSUMER PROMOTIONAL LABELING AND ADVERTISEMENTS	
А.	Probability Presentations	.3
1. 2	Absolute Frequencies and Percentages Relative Frequencies	3 4
B.	Formatting Quantitative Efficacy or Risk Information	.5
C.	Visual Aids	.6
D.	Quantitative Efficacy or Risk Information from the Control Group	8
REFE	RENCES	9

Draft — Not for Implementation

Presenting Quantitative Efficacy and Risk Information in Direct-to Consumer Promotional Labeling and Advertisements Guidance for Industry¹

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.

11 12

13

16

4

5 6

7

8

9

10

14 15 **I. INTRODUCTION**

17 This draft guidance provides recommendations for presenting quantitative efficacy and risk

18 information in direct-to-consumer (DTC) promotional labeling and advertisements for

19 prescription human drugs and biological products and prescription animal drugs and in DTC

20 promotional labeling for over-the-counter animal drugs² (collectively *promotional materials*).³

21 For the purposes of this guidance, quantitative efficacy and risk information refers to information

that numerically addresses the likelihood or magnitude of a drug's effectiveness or risks.

23

The guidance outlines FDA's recommendations for how firms⁴ that include quantitative efficacy
 or risk information in DTC promotional materials for their drugs can make the language and
 presentation more consumer-friendly.⁵ These recommendations apply to DTC promotional

⁴ The term *firms* in this guidance refers to manufacturers, packers, and distributors of prescription drugs, as described in this guidance, and over-the-counter animal drugs, including their representatives.

¹ This guidance has been prepared by the Office of Prescription Drug Promotion in the Center for Drug Evaluation and Research, in consultation with the Center for Biologics Evaluation and Research and the Center for Veterinary Medicine at the Food and Drug Administration.

 $^{^{2}}$ The term *drugs* in this guidance refers to prescription human and animal drugs, prescription biologics, and overthe-counter animal drugs.

³ *Promotional labeling* is generally any labeling other than the FDA-required labeling. Examples of materials that may be considered promotional labeling, such as brochures, booklets, and mailing pieces, are described in 21 CFR 202.1(1)(2). The Federal Food, Drug, and Cosmetic Act (FD&C Act) does not define what constitutes an *advertisement*, but FDA regulations provide several examples, including "advertisements in published journals, magazines, other periodicals, and newspapers, and advertisements broadcast through media such as radio, television, and telephone communication systems" (21 CFR 202.1(1)(1)).

⁵ This guidance is not intended to describe whether or when a presentation of quantitative efficacy or risk information would be truthful or non-misleading. FDA reminds firms that they are responsible for ensuring that their promotional materials are truthful and non-misleading and that they comply with applicable statutory and regulatory requirements. See, e.g., 21 U.S.C. 352(a), 352(n), and 321(n); 21 CFR 1.21; and 202.1(e)(5)(i) through (iii). Additionally, we note that there may be ways other than the recommendations provided in this draft guidance that would make presentations of quantitative efficacy or risk information consumer-friendly.

Draft — Not for Implementation

- materials regardless of the medium in which they are presented (e.g., print, electronic, 27
- 28 audiovisual, broadcast).
- 29

30 This guidance covers the following topics for presenting quantitative efficacy and risk

31 information in DTC promotional materials:

32 33

35

36

- Presenting probability information in terms of absolute frequencies, percentages, and 34 relative frequencies
 - Formatting quantitative efficacy or risk information
 - Using visual aids to illustrate quantitative efficacy or risk information
- 37 • Providing quantitative efficacy or risk information for the treatment group and the control 38 group
- 39

40 In general, FDA's guidance documents do not establish legally enforceable responsibilities.

- 41 Instead, guidances describe the Agency's current thinking on a topic and should be viewed only
- 42 as recommendations, unless specific regulatory or statutory requirements are cited. The use of 43 the word *should* in Agency guidances means that something is suggested or recommended, but
- 44 not required.
- 45

46

47 II. BACKGROUND

48

49 The Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulations 50 generally require that promotional labeling and advertisements for drugs, including materials 51 directed toward consumers, be truthful and non-misleading, convey information about a drug's 52 efficacy and its risks in a balanced manner, and reveal material facts about the drug.⁶ Firms 53 generally have flexibility with respect to the presentation of efficacy and risk information about 54 their products so long as the presentation is not false or misleading and complies with other 55 applicable statutory and regulatory requirements. When firms develop DTC promotional 56 materials, they should consider how to best convey information about a drug's efficacy and risks 57 so the audience understands it. This includes consideration of whether to provide efficacy and 58 risk information by using words, numbers, or visual aids, or a combination of these elements. 59 60 In recent years, FDA has observed an increase in quantitative presentations of efficacy and risk information in DTC promotional materials submitted to the Agency. Recent research on the

61

- 62 communication of treatment information suggests that consumers can recall and comprehend
- 63 efficacy and risk information when it is provided quantitatively (Buchter et al. 2014;
- 64 O'Donoghue et al. 2014b; Schwartz et al. 2007; Schwartz et al. 2009; Sullivan et al. 2015;
- Trevena et al. 2013; West et al. 2013; Woloshin et al. 2004). When compared to qualitative 65
- 66 descriptions of efficacy and risk information, quantitative information can improve consumers'
- 67 accuracy in estimating the drug's benefits and risks (Sullivan et al. 2015; West et al. 2013). This
- 68 is due in part to how consumers differ in their interpretations of qualitative descriptors (e.g.,
- 69 rare, common, most) and how the context in which qualitative terms are presented can affect
- 70 how consumers understand them (Buchter et al. 2014; Fagerlin et al. 2007; Lipkus 2007;

⁶ See, e.g., 21 U.S.C. 352(a), 352(n), and 321(n); 21 CFR 1.21; and 202.1(e)(5)(i) through (iii).

Draft — Not for Implementation

- Visschers et al. 2009). Quantitative efficacy or risk information may offer more precision than
 qualitative information, which consumers can use to form more accurate perceptions about the
 drug (Lipkus 2007).
- 74
- 75 Firms should ensure that DTC promotional materials containing quantitative efficacy or risk
- 76 information are accurate and understandable. FDA understands that firms may experience
- challenges when determining how to present this kind of quantitative information in DTC
- 78 promotional materials. For these reasons, FDA is issuing this guidance to provide
- 79 recommendations for presenting quantitative efficacy and risk information in DTC promotional
- materials and to encourage firms to follow these recommendations when including such
 information in their DTC promotional materials.
- 82
- The examples in this guidance are intended to illustrate recommended approaches to presenting
 quantitative efficacy and risk information in DTC promotional materials. Each example is meant
 to address a specific concept described in the guidance; a given example may not illustrate every
- recommendation outlined. The examples do not encompass every potential promotional scenario
- 87 or consideration and do not necessarily reflect an evaluation of a complete promotional piece,
- 88 including whether the piece complies with other applicable requirements. All recommendations
- discussed in this guidance should be taken into consideration even if not expressly illustrated inan example.
- 91
- 92

93 III. RECOMMENDATIONS FOR PRESENTING QUANTITATIVE EFFICACY AND 94 RISK INFORMATION IN DIRECT-TO-CONSUMER PROMOTIONAL 95 LABELING AND ADVERTISEMENTS

96 97

98

A. Probability Presentations

99 Firms should consider the following recommendations when presenting quantitative probability100 information about their drug's efficacy and risks.

- 101 102
- 1. Absolute Frequencies and Percentages

103 Firms presenting quantitative efficacy or risk probabilities in DTC promotional materials should 104 105 convey the information in terms of absolute frequencies (e.g., 57 out of 100) or percentages 106 (57%). Research suggests that using these formats to express probabilities when communicating 107 health information can improve consumers' comprehension and ability to recall the information 108 (Lipkus 2007; Zipkin et al. 2014). Additionally, consumers receiving information about a drug's 109 efficacy and risk rates in terms of absolute frequencies or percentages can more easily process 110 and evaluate the information than when the same information is in a format that requires them to 111 perform a calculation to interpret the probabilities (Lipkus 2007; O'Donoghue et al. 2014b; 112 Sullivan et al. 2015). 113

114Example 1:A firm is developing a magazine advertisement and includes a presentation115showing that in clinical trials, most patients experienced a response after

Draft — Not for Implementation

		Draft — Not for Implementation			
116		12 weeks of treatment with Drug X. The firm wants to add numeric values to the			
117		presentation to help consumers understand this information.			
118					
119		To communicate this information in a manner that will facilitate consumer			
120		comprehension, the firm presents the information as an absolute frequency: In a			
121		clinical trial, 78 out of 100 patients experienced a response after 12 weeks of			
122		treatment with Drug X.			
123	F 1.0				
124	Example 2:	A firm plans to include quantitative information in a patient mailer for Drug X			
125		about the most common adverse reaction associated with Drug X: nausea.			
126					
127		To allow consumers to easily process this information, the firm presents the			
128		information as a percentage: In a clinical trial, 45% of patients experienced			
129		nausea during 12 weeks of treatment with Drug X, compared to 18% of patients			
130		during treatment with Drug Y.			
131	2				
132 133	2.	Relative Frequencies			
133	December of	casts that consumers do not understand relative frequencies (e.g. 220/ reduction in			
134	-	gests that consumers do not understand relative frequencies (e.g., 33% reduction in times as likely to experience a side effect) in health communications as easily as			
135	• •	nd other formats for presenting probabilities, such as absolute frequencies or			
130		Covey 2007; Fagerlin et al. 2007; Zipkin et al. 2014). Consumers may also find the			
137		sk probability described as a relative frequency harder to comprehend and more			
138					
140	favorable as compared to the absolute frequency, which could lead to consumers' over- or underestimating how well the drug works or the magnitude of the rick associated with the drug				
140	underestimating how well the drug works or the magnitude of the risk associated with the drug (Ancker et al. 2006; Covey 2007; Zipkin et al. 2014).				
142	(Thekei et al	. 2000, Covey 2007, Zipkin et al. 2014).			
143	If firms choo	se to present efficacy or risk probabilities as relative frequencies, they should add			
144	context to the relative frequency presentation to improve consumers' ability to accurately				
145	understand the efficacy or risk information. Specifically, firms should include the corresponding				
146	absolute probability measures in presentations of relative frequency measures to provide the				
147	-	n a way that does not require further calculation about the effect being			
148		d (Covey 2007; O'Donoghue et al. 2014b; Sullivan et al. 2015).			
149					
150	Example 3:	A firm is developing a DTC television advertisement for Drug X, which is			
151	<u>*</u>	indicated to reduce the risk of stroke. In a clinical trial, the following absolute			
152		risk reductions were observed: 1% of patients treated with Drug X had a stroke,			
153		compared to 2% of patients in the control group. This represents a 50% relative			
154		reduction in risk of stroke.			
155					
156		To communicate this information in the DTC television advertisement in a			
157		manner that will facilitate consumer comprehension, the firm presents the			
158		absolute risk percentages in direct conjunction with the 50% relative risk			
159		reduction information: In a clinical trial, Drug X reduced the risk of stroke by			
160		50% (1% of patients treated with Drug X had a stroke, compared to 2% of			
161		patients in the control group).			

Draft — Not for Implementation

162					
163	В.	Formatting Quantitative Efficacy or Risk Information			
164					
165	Firms that pro	ovide quantitative efficacy or risk information about their drugs in DTC			
166	-	naterials should incorporate the following formatting recommendations:			
167	1				
168	• Preser	t the information in the same numerical format throughout a promotional labeling			
169		or advertisement (Lipkus 2007; Trevena et al. 2013). For example, firms providing			
170	-	robabilities about two efficacy outcomes should provide both probabilities as			
171	1	te frequencies or both probabilities as percentages. Firms should also consistently			
172		sterize efficacy or risk information quantitatively throughout a promotional piece,			
173	rather than alternating between qualitative descriptors and quantitative information to				
174		be similar information or concepts.			
175					
176	• Use fr	equencies with the same denominator when providing more than one absolute			
177		ency and consider using denominators that are multiples of 10 (Fagerlin et al. 2007;			
178	-	s 2007; Trevena, et al. 2013; Visschers et al. 2009).			
179	1				
180	• Expre	ss probabilities using whole numbers to the extent that the probabilities in whole			
181	-	ers accurately reflect the numerical value being described in the promotional piece			
182		us 2007; Zipkin et al. 2014). ⁷ Where a whole number would not be appropriate,			
183	· -	should express the value as is (e.g., as a decimal) instead of rounding the value up			
184		vn to the nearest whole number. For example, firms should not round probabilities			
185		an 1 to the nearest whole number. Similarly, firms should not round probabilities			
186	to the	nearest whole number when comparing probabilities that are so close in value that			
187	the dif	fference between the probabilities would be lost if the values were expressed as a			
188	whole	number or numbers. Firms also should ensure that quantitative probability			
189	inforn	nation about a particular risk does not minimize or deter from information about the			
190	severi	ty of the risk. For example, firms should not disproportionately emphasize the low			
191	probal	bility of a serious risk occurring as a way to detract from the seriousness of that			
192	risk.				
193					
194	Example 4:	A firm is developing a consumer brochure for Drug X and is considering whether			
195		to describe quantitative information about moderate symptom relief in patients			
196		treated with Drug X and treated with placebo in terms of absolute frequencies (9			
197		out of 10 and 3 out of 10, respectively) or as percentages (90% and 30%,			
198		respectively).			
199					
200		Although either probability measure would be appropriate to describe these			
201		outcomes, to help consumers process the information, the firm should provide the			
202		outcomes for both the treatment and placebo groups in the same format (i.e., both			
203		outcomes as absolute frequencies or both outcomes as percentages): In patients			

⁷ For values greater than 1, to express a value to the nearest whole number, the following principles apply: For amounts falling exactly halfway between two whole numbers or higher (e.g., 2.5 to 2.99), round up (e.g., 3); for values less than halfway between two whole numbers (e.g., 2.01 to 2.49), round down (e.g., 2).

Draft — Not for Implementation

204 treated with Drug X, 9 out of 10 patients experienced moderate symptom relief, 205 compared to 3 out of 10 patients who received placebo. Alternatively: In 206 patients treated with Drug X, 90% of patients experienced moderate symptom 207 relief, compared to 30% of patients who received placebo. 208 209 In a clinical trial for Drug X, 54% of patients treated with Drug X experienced Example 5: 210 moderate symptom relief and 19% of patients treated with Drug X experienced 211 complete symptom relief, compared to 28% of patients treated with placebo and 212 2% of patients treated with placebo, respectively. The firm is developing a 213 patient booklet for Drug X that contains the following information: In a clinical 214 trial, the majority of patients experienced moderate symptom relief after treatment 215 with Drug X, and 19% of patients experienced complete symptom relief. In patients treated with placebo, less than half of patients experienced moderate 216 217 symptom relief and 2% of patients experienced complete symptom relief. 218 219 To present the information consistently, the firm should include the "*majority of* 220 patients (54%)" and "less than half of patients (28%)" in the proposed patient 221 booklet. Alternatively, the firm could consistently present only the quantitative 222 information throughout the piece (e.g., "...54% of patients treated with Drug X experienced moderate symptom relief...," "....28% of patients treated with placebo 223 224 *experienced moderate symptom relief...*"). 225 226 C. **Visual Aids** 227 228 When DTC promotional materials contain quantitative efficacy or risk information, visual aids 229 such as graphs, tables, and icon arrays can be used to illustrate the information and put the

numerical values in context. Visual representations of efficacy and risk in DTC promotional
materials improve consumer comprehension of numeric values by illustrating patterns,
summarizing the data, and reducing the amount of mental calculations the consumer must
perform to extract meaning from the quantitative information (Ancker et al. 2006; Fagerlin et al.
2007; Lipkus 2007). Moreover, visual aids can improve consumers' ability to accurately
understand how well a drug works and support decision making (Fagerlin et al. 2007; GarciaRetamero and Cokely 2013; Sullivan et al. 2016; Zipkin et al. 2014).

237


238 Visual aids in DTC promotional materials help consumers comprehend quantitative efficacy and 239 risk information, but all visual aid designs are not equally effective in conveying all types of 240 information (Fagerlin et al. 2007; Sullivan et al. 2016). Therefore, we recommend that firms 241 select the visual aid design that best communicates the quantitative efficacy or risk information 242 being presented. When choosing a visual aid to express quantitative efficacy or risk information 243 about a drug, firms should carefully consider the communication's purpose and objectives 244 (Ancker et al. 2006; Fagerlin et al. 2007). For example, a bar graph is an appropriate format for 245 visually depicting comparisons between probabilities, whereas a line graph is more useful for 246 illustrating trends or changes over time (Ancker et al. 2006; Fagerlin et al. 2007; Lipkus 2007). 247 Additionally, firms should consider the following general recommendations when designing 248 visual aids to illustrate quantitative efficacy or risk information in their DTC promotional

249 materials:

Draft — Not for Implementation

250 251 Explain the purpose of the visual aid clearly and accurately and define the elements • 252 displayed (Garcia-Retamero and Cokely 2013; Lipkus 2007). For example, firms should include a title, header, or caption (written or oral depending on the media) and identify 253 254 the visual aid's variables, scales, and axes (when applicable). 255 256 Make visual displays of numeric information proportionate to the quantity being • 257 described (Ancker et al. 2006; Lipkus 2007). For example, the height of a bar on a bar 258 graph should be proportionate to the quantity it represents. 259 260 Include visual representations of both the numerator and denominator of ratios or • frequencies (Ancker et al. 2006). For example, an icon array should illustrate the number 261 of people who experienced the effect (numerator) out of the total number of people 262 263 studied (denominator). 264 265 Infection is a risk associated with the use of Drug X. The firm responsible Example 6: 266 for Drug X wants to include a visual aid on Drug X's consumer website to 267 communicate information from Drug X's approved labeling about the number of patients who did not experience an infection, those who experienced a mild to 268 269 moderate infection, and those who experienced a severe or life-threatening 270 infection after treatment with Drug X compared to patients treated with placebo. 271 272 *The firm prepares a bar graph to present this information because it best* 273 facilitates the comprehension of visual comparisons between probabilities. As 274

illustrated below, the firm includes a title that describes what the bar graph portrays, labels the scales and variables, and ensures that the values graphically displayed are proportionate to the quantities being described.



278 279

275

276 277

279 280 281

D. Quantitative Efficacy or Risk Information from the Control Group

Firms that provide quantitative efficacy or risk information about a drug in DTC promotional materials should provide quantitative information from both the treatment group and the relevant control group. Information from the control group plays an important role in evaluating a drug's

Draft — Not for Implementation

285 benefits and risks (O'Donoghue et al. 2014a). Including efficacy or risk measures observed in 286 the control group quantitatively when providing corresponding quantitative measures observed in 287 the treatment group improves consumers' ability to process and comprehend the drug's efficacy 288 and risks and can lead to more-informed decision making (O'Donoghue et al. 2014a; Schwartz et 289 al. 2009). Research suggests that consumers can use the information about the control group to 290 form accurate perceptions about a drug's efficacy and risk (O'Donoghue et al. 2014a; Schwartz 291 et al. 2009; Sullivan et al. 2013). When including control group information in promotional 292 materials, firms should also ensure that they accurately describe the comparator used in the 293 control group. 294 295 In a clinical trial of 173 participants, 68% of patients who were treated with Drug Example 7: 296 X plus a sulfonylurea experienced a reduction in blood glucose levels, while 33% 297 of patients treated with a sulfonylurea alone experienced a reduction in blood 298 glucose levels. The firm is developing a social media web page for Drug X and 299 includes a presentation that 68% of patients treated with Drug X plus a 300 sulfonylurea experienced a reduction in blood glucose levels. 301 302 The firm should also include that 33% of patients treated with a sulfonylurea 303 alone experienced a reduction in blood glucose levels. 304

	Draft — Not for Implementation				
305	REFERENCES				
306					
307	Ancker, JS, Y Senathirajah, R Kukafka, and JB Starren, 2006, Design Features of Graphs in				
308	Health Risk Communication: A Systematic Review, J Am Med Inform Assoc, 13(6):608–618.				
309					
310 311	Buchter, RB, D Fechtelpeter, M Knelangen, M Ehrlich, and A Waltering, 2014, Words or numbers? Communicating Risk of Adverse Effects in Written Consumer Health Information: A				
312 313	Systematic Review and Meta-Analysis, BMC Med Inform Decis Mak, 14:76.				
314 315 316	Covey J, 2007, A Meta-Analysis of the Effects of Presenting Treatment Benefits in Different Formats, Med Decis Making, 27(5):638–654.				
317 318 319	Fagerlin, A, PA Ubel, DM Smith, and BJ Zikmund-Fisher, 2007, <i>Making Numbers Matter:</i> <i>Present and Future Research in Risk Communication</i> , Am J Health Behav, 31(Suppl 1):S47–56.				
320 321	Garcia-Retamero, R and ET Cokely, 2013, <i>Communicating Health Risks with Visual Aids</i> , Curr Dir Psychol Sci, 22(5):392–399.				
322					
323 324 325	Lipkus, IM, 2007, Numeric, Verbal, and Visual Formats of Conveying Health Risks: Suggested Best Practices and Future Recommendations, Med Decis Making, 27(5):696–713.				
323 326	O'Donoghue, AC, HW Sullivan, and KJ Aikin, 2014a, Randomized Study of Placebo and				
320	Framing Information in Direct-to-Consumer Print Advertisements for Prescription Drugs, Ann				
327 328 329	Behav Med, 48(3):311–322.				
330	O'Donoghue, AC, HW Sullivan, KJ Aikin, D Chowdhury, RR Moultrie, and DJ Rupert, 2014b,				
331	Presenting Efficacy Information in Direct-to-Consumer Prescription Drug Advertisements,				
332	Patient Educ Couns, 95(2):271–280.				
333	1 attent Educ Couris, <i>35(2).27</i> 1–280.				
334	Schwartz, LM, S Woloshin, and HG Welch, 2007, The Drug Facts Box: Providing Consumers				
335	with Simple Tabular Data on Drug Benefit and Harm, Medical Decision Making, 27:655–662.				
336	with Simple Tabular Data on Drug Benejit and Harm, Medical Decision Making, 27.055–002.				
337	Schwartz, LM, S Woloshin, and HG Welch, 2009, Using a Drug Facts Box to Communicate				
338	Drug Benefits and Harms: Two Randomized Trials, Ann Intern Med, 150(8):516–527.				
339	Drug Benefits and Harms. Two Randomized Triats, Ann Intern Med, 150(8).510–527.				
339 340	Sullivan, HW, AC O'Donoghue, and KJ Aikin, 2013, Presenting Quantitative Information About				
340 341	Placebo Rates to Patients, JAMA Intern Med, 173(21):2006–2007.				
342	<i>Flacedo Rales lo Fallenis</i> , JAMA Intern Med, 175(21).2000–2007.				
	Sullivon LIW AC O'Denechus and KL Ailtin 2015 Communicating Banafit and Bigh				
343	Sullivan, HW, AC O'Donoghue, and KJ Aikin, 2015, <i>Communicating Benefit and Risk</i>				
344	Information in Direct-to-Consumer Print Advertisements: A Randomized Study, Ther Innov				
345	Regul Sci, 49(4):493–502.				
346	Sullivon IIW AC O'Denechus KI Ailin D Chaudhury DD Maultrie and DI Denert 2016				
347	Sullivan, HW, AC O'Donoghue, KJ Aikin, D Chowdhury, RR Moultrie, and DJ Rupert, 2016,				
348	Visual Presentations of Efficacy Data in Direct-to-Consumer Prescription Drug Print and Tologistic Advertisemental A Pandomized Study Patient Educ Counc. 00:700, 700				
349	Television Advertisements: A Randomized Study, Patient Educ Couns, 99:790–799.				
350					

Draft — Not for Implementation

- 351 Trevena, LJ, BJ Zikmund-Fisher, A Edwards, W Gaissmaier, M Galesic, PKJ Han, J King, ML
- Lawson, SK Linder, I Lipkus, E Ozanne, E Peters, D Timmermans, and S Woloshin, 2013,
- 353 Presenting Quantitative Information About Decision Outcomes: A Risk Communication Primer
- *for Patient Decision Aid Developers*, BMC Med Inform Decis Mak, 13(Supple 2):S7.
- 355
- 356 Visschers, VH, RM Meertens, WW Passchier, NN De Vries, 2009, Probability Information in
- 357 Risk Communication: A Review of the Research Literature, Risk Anal, 29(2):267–287.
- 358
- 359 West, SL, LB Squiers, L McCormack, BG Southwell, ES Brouwer, M Ashok, L Lux, V
- 360 Boudewyns, A O'Donoghue, and HW Sullivan, 2013, Communicating Quantitative Risks and
- 361 Benefits in Promotional Prescription Drug Labeling or Print Advertising, Pharmacoepidemiol
- 362 Drug Saf, 22(5):447–458.
- 363

364 Woloshin, S, LM Schwartz, and HG Welch, 2004, The Value of Benefit Data in Direct-to-

- 365 *Consumer Drug Ads*, Health Aff, Suppl Web Exclusives, W4:234–245.
- 366
- 367 Zipkin, DA, CA Umscheid, NL Keating, E Allen, K Aung, R Beyth, S Kaatz, DM Mann, JB
- 368 Sussman, D Korenstein, C Schardt, A Nagi, R Sloane, and DA Feldstein, 2014, *Evidence-Based*
- 369 Risk Communication: A Systematic Review, Ann Intern Med, 161(4):270–280.